Patient-Led Research Funding and Infrastructure
If epistemic injustice is the context, patient-led research infrastructure is the response. ME/CFS patients and their organizations have built funding mechanisms, research networks, and data repositories that operate in parallel to β and increasingly in partnership with β formal research institutions.
Two organizations exemplify the patient-funded research model in ME/CFS:
Solve ME/CFS Initiative: The You + ME Registry, launched in 2020, is a patient-powered research platform with over 4,200 participants (3,033 ME/CFS, 833 long COVID, 473 controls as of 2021), growing at approximately 72 new registrants per week (Ramiller et al. 2022). The mobile app captures longitudinal symptom tracking on a 0β4 severity scale. The registry is designed to harmonize with other ME/CFS data collection efforts and enables researchers to access de-identified data for analysis. Solve ME also provides Ramsay Research Grants to early-career investigators β a funding mechanism that explicitly targets the research-capacity gap created by minimal federal funding for ME/CFS.
Open Medicine Foundation (OMF): OMF funds and coordinates multi-site collaborative research through its OMF Collaborative Research Network, including the Severely Ill Patient Study (the largest systematic study of severe/very severe ME/CFS patients), metabolomics and proteomics studies, and the Medical Education Departmentβs clinician education initiatives. OMFβs funding is predominantly patient-donated β a model in which the affected community directly finances its own research infrastructure.
These organizations are significant not only for the research they fund but for the model they represent: patient communities identifying research priorities, raising funds, and directing those funds toward investigator-initiated studies that align with community-identified needs. This model inverts the traditional funding structure β in which institutions set priorities and patients have limited input β and represents a form of epistemic self-determination. (Certainty: 0.70 β organizational self-description and publicly available data; You + ME registry statistics from published description; no independent evaluation of funding-model impact exists.)
Consequence: These organizations demonstrate that patient communities can function as research funders and infrastructure-builders, not just as research subjects. For a disease that receives substantially less NIH research funding per patient than diseases of comparable prevalence and severity, patient-funded research fills a gap that federal funding leaves open. The model also changes the epistemic relationship: when patients fund the research, they shape the questions. Severity applicability: the You + ME registry includes mild, moderate, and severe patients; the OMF Severely Ill Patient Study specifically addresses the most understudied population.
The patient-funded model has structural limitations. Patient communities raising funds from each other concentrate the financial burden on an already economically disadvantaged population β the same chapter that documents 75% of patients unable to work also documents the community funding its own research. This creates a perverse incentive: the more the federal government underfunds ME/CFS research, the more the patient community must pay to fill the gap, deepening the economic burden on a population already impoverished by disease. The model is also vulnerable to donor fatigue, fundraising cycles, and the concentration of funding influence among the most-abled patients (those well enough to organize, advocate, and donate).
Second, no independent evaluation has compared the scientific output of patient-funded research to federally-funded research in ME/CFS β in terms of publications, citation impact, clinical translation, or patient benefit. The claim that patient-funded research fills a gap is descriptive. The claim that it fills the gap effectively is untested. (Certainty: 0.60 β inferred from organizational data; no evaluation studies exist.)
Consequence: Patient-funded research is a necessary response to systematic underfunding, but it should not be normalized as the solution. The goal is not to replace federal funding with patient donations β it is to demonstrate that ME/CFS research generates returns on investment that justify federal funding at parity with diseases of comparable prevalence and severity. The patient-funded model is a proof of concept, not a sustainable funding architecture. Severity applicability: patient-funded infrastructure benefits all severity levels, but the fundraising burden falls disproportionately on patients well enough to participate economically.